A1-2: Cost-Effectiveness of Interleukin 28B Genotype-Guided Protease Inhibitor Therapy in Treatment-Naive Patients with Hepatitis C Virus Genotype 2 or 3

ABSTRACT:

Background/Aims

The addition of protease inhibitors to standard of care (SOC) dramatically increases treatment response in Hepatitis C Virus (HCV) genotype 1 patients. Moreover, Interleukin 28B (IL28B) genotyping helps predict responsiveness for these patients. However, the economic implications of incorporating IL28B genotyping in HCV genotype 2 or 3 infected patients are unknown. This study used a treatment algorithm that included IL28B genotype-guided therapy to examine the short and long-term cost-effectiveness of utilizing these single-nucleotide polymorphisms in treatment-naïve HCV genotype 2 or 3 infected patients.

Methods

A treatment algorithm was constructed to reflect a therapy regimen for treatment-naïve patients with HCV genotype 2 or 3 infection using pegylat

SUBMITTER: Bock J 

PROVIDER: S-EPMC3788547 | biostudies-literature | 2013 Sep

REPOSITORIES: biostudies-literature